AtriCure, Inc.

AtriCure, Inc. is a specialized medical device company focused on developing and delivering innovative surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management. The company's core offerings include devices such as the Isolator® Synergy™ Ablation System—the first FDA-approved device for the treatment of persistent Afib—and the AtriClip® Left Atrial Appendage Exclusion System, which is among the most widely adopted devices for LAA management worldwide. AtriCure’s products serve electrophysiologists and cardiothoracic surgeons, enabling them to address even the most complex cardiac arrhythmias and improve patient outcomes. In addition to Afib and LAA technologies, AtriCure provides specialized cryoablation tools designed to offer pain management solutions in cardiac and thoracic surgery. The company is committed to advancing clinical science, rigorous quality standards, and provider education, thereby playing a key role in reducing the global burden of Afib and supporting improved patient care in cardiovascular medicine.